CIK 0001708599 · Non-accelerated filer<br>Smaller reporting company
Serina Therapeutics, Inc.
Sign in to watch- Ticker
- SER
- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- AL
- Entity type
- operating
- EIN
- 821436829
- Phone
- (256) 327-9630
- Business address
- 601 GENOME WAY, SUITE 2001, HUNTSVILLE, AL, 35806
- Former names
- AgeX Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 43 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-29 | Moreadith Randall Chief Scientific Officer | Option exercise 10b5-1 | +4,196 | $0.06 | $252 | 4,196 |
| 2025-07-29 | Moreadith Randall Chief Scientific Officer | Sale 10b5-1 | −4,196 | $6.50 | $27K | 0 |
| 2025-07-29 | Moreadith Randall Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −4,196 | 484,490 | ||
| 2025-07-28 | Moreadith Randall Chief Scientific Officer | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| 2025-07-28 | Moreadith Randall Chief Scientific Officer | Sale | −6,500 | $5.89 | $38K | 0 |
| 2025-07-28 | Moreadith Randall Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −6,500 | 488,686 | ||
| 2025-07-21 | Moreadith Randall Chief Scientific Officer | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| 2025-07-21 | Moreadith Randall Chief Scientific Officer | Sale | −6,500 | $5.34 | $35K | 0 |
| 2025-07-21 | Moreadith Randall Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −6,500 | 495,186 | ||
| 2025-07-14 | Moreadith Randall Chief Scientific Officer | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| 2025-07-14 | Moreadith Randall Chief Scientific Officer | Sale | −6,500 | $5.01 | $33K | 0 |
| 2025-07-14 | Moreadith Randall Chief Scientific Officer | Option exercise · Stock Option (right to buy) | −6,500 | 501,686 | ||
| 2025-07-07 | Moreadith Randall Chief Scientific Officer | Option exercise 10b5-1 | +6,500 | $0.06 | $390 | 6,500 |
| 2025-07-07 | Moreadith Randall Chief Scientific Officer | Sale 10b5-1 | −6,500 | $5.67 | $37K | 0 |
| 2025-07-07 | Moreadith Randall Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −6,500 | 508,186 | ||
| 2025-06-30 | Moreadith Randall Chief Scientific Officer | Option exercise 10b5-1 | +6,500 | $0.06 | $390 | 6,500 |
| 2025-06-30 | Moreadith Randall Chief Scientific Officer | Sale 10b5-1 | −6,500 | $5.78 | $38K | 0 |
| 2025-06-30 | Moreadith Randall Chief Scientific Officer | Option exercise · Stock Option (right to buy) 10b5-1 | −6,500 | 514,686 | ||
| 2025-05-22 | Brannan Stephen K. Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2025-04-08 | Venkatesan Jay Director | Grant or award · Series A Convertible Preferred Stock | +96,525 | $5.18 | $500K | 96,525 |
Page 8 of 12 · 223 trades